Treatment Outcomes of Nebulized High-dose Inhaled Corticosteroid as Add-on Therapy in Asthma Exacerbation at Emergency Department: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201214001

Enrollment

Registered

2020-12-14

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute asthma exacerbation acute asthma exacerbation, emergency department, high dose inhaled corticosteroids, randomize controlled trial

Interventions

Normal saline ,Corticosteroids

NSS 6 ml nebulized q 20 minutes x 3 doses , Budesonide 3000 micrograms (6 ml) nebulized q 20 minutes x 3 doses

Placebo Comparator Drug,Experimental Drug

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Emergency department patient who diagnosed of acute asthma exacerbation

Exclusion criteria

Exclusion criteria: 1. respiratory failure who require intubation 2. history of corticosteroids allergy 3. diagnosis of COVID-19, pulmonary TB, and pneumonia 4. patients who refuse to participate

Design outcomes

Primary

Measure	Time frame
treatment outcomes 48 hours length of ED stay, ED revisit with in 48 hrs after ED discharge and admission rate	—

Secondary

Measure	Time frame
treatment outcomes 48 hours after ED discharge dyspnea scale, pulmonary functions, length of hospital stay, and home exacerbation after ED discharge	—

Countries

Thailand

Contacts

Public ContactKumpol Kornthatchapong

Department of Emergency medicine, Faculty of medicine, Thammasat university

kump29@gmail.com66954951555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026